ESSA Bancorp logo

ESSA BancorpNASDAQ: ESSA

Profile

Country:

United States

IPO:

04 April 2007

Next earnings report:

24 January 2025

Last dividends:

16 September 2024

Next dividends:

N/A
$203.44 M
-9%vs. 3y high
34%vs. sector
-3%vs. 3y high
26%vs. sector
-16%vs. 3y high
25%vs. sector
-10%vs. 3y high
47%vs. sector

Price

after hours | 48 min ago
$20.08+$0.12(+0.60%)
$16.43 M$4.18 M

Analysts recommendations

Institutional Ownership

ESSA Latest News

ESSA Bancorp, Inc. Declares Quarterly Dividend
accesswire.com20 November 2024 Sentiment: -

STROUDSBURG, PA / ACCESSWIRE / November 20, 2024 / ESSA Bancorp, Inc. (NASDAQ:ESSA), the holding company for ESSA Bank & Trust, today announced that its Board of Directors declared a dividend of fifteen cents ($0.15) per share. The dividend is payable to shareholders of record as of December 16, 2024, payable on December 30, 2024.

ATTENTION ESSA Pharma Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
accesswire.com16 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
accesswire.com16 November 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / November 16, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

ATTENTION ESSA Pharma Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
accesswire.com14 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 14, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
accesswire.com14 November 2024 Sentiment: NEGATIVE

NEW YORK CITY, NY / ACCESSWIRE / November 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

ESSA Pharma Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - EPIX
accesswire.com12 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ESSA Pharma Inc. ("ESSA Pharma Inc.") (NASDAQ:EPIX) concerning possible violations of federal securities laws. On October 31, 2024, ESSA announced that it was ending its Phase 2 trial for a prostate cancer treatment which tested masofaniten with enzalutamide versus enzalutamide alone in patients with metastatic castration-resistant prostate cancer who had not yet used second-generation antiandrogens.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ESSA Pharma Inc. - EPIX
accesswire.com01 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of ESSA Pharma Inc. ("ESSA" or the "Company") (NASDAQ:EPIX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

ESSA Bancorp, Inc. Announces Fiscal Fourth Quarter, Full Year 2024 Financial Results
accesswire.com23 October 2024 Sentiment: POSITIVE

STROUDSBURG, PA / ACCESSWIRE / October 23, 2024 / ESSA Bancorp, Inc. (the "Company") (NASDAQ:ESSA), the holding company for ESSA Bank & Trust (the "Bank"), a $2.2 billion asset financial institution providing full service commercial and retail banking, asset management and trust, and investment services in eastern Pennsylvania, today announced financial results for the fiscal fourth quarter and full year ended September 30, 2024. Net income was $4.2 million, or $0.44 per diluted share, for the three months ended September 30, 2024, compared with $4.6 million, or $0.47 per diluted share, for the three months ended September 30, 2023.

ESSA Pharma Presents Updated Phase 1/2 Masofaniten (EPI-7386) Clinical Data at the 2024 ESMO Congress
prnewswire.com13 September 2024 Sentiment: POSITIVE

Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion currently underway at the RP2CDs of masofaniten 600 mg BID in combination with enzalutamide 160 mg QD Across all dosing cohorts, 88% of patients achieved PSA90, 69% of patients achieved PSA90 in less than 90 days, and 63% of patients achieved PSA

ESSA Pharma to Present at the 2024 Cantor Global Healthcare Conference
prnewswire.com11 September 2024 Sentiment: POSITIVE

SOUTH SAN FRANCISCO, Calif. and VANCOUVER, BC , Sept.

  • 1(current)

What type of business is ESSA Bancorp?

ESSA Bancorp, Inc. operates as a bank holding company for ESSA Bank & Trust that provides a range of financial services to individuals, families, and businesses in Pennsylvania. The company accepts savings accounts, interest bearing demand accounts, checking accounts, money market accounts, club accounts, certificates of deposit and IRAs, and other qualified plan accounts, as well as commercial checking accounts. It also provides first mortgage loans for the purchase, construction, or refinancing of one- to four-family residential real estate property; commercial real estate loans; home equity loans and lines of credit; auto loans; and commercial and other consumer loans, as well as loans secured by deposits and personal unsecured loans. In addition, the company offers insurance benefits consulting services, such as health insurance, life insurance, short term and long term disability, dental, vision, 401(K) retirement planning, and individual health products, as well as asset management and trust, and investment services. It operates community offices in Monroe County, Lehigh County, Northampton County, Lackawanna County, Luzerne County, Chester County, Delaware County, and Montgomery County. ESSA Bancorp, Inc. was founded in 1916 and is headquartered in Stroudsburg, Pennsylvania.

What sector is ESSA Bancorp in?

ESSA Bancorp is in the Financial Services sector

What industry is ESSA Bancorp in?

ESSA Bancorp is in the Banks - Regional industry

What country is ESSA Bancorp from?

ESSA Bancorp is headquartered in United States

When did ESSA Bancorp go public?

ESSA Bancorp initial public offering (IPO) was on 04 April 2007

What is ESSA Bancorp website?

https://www.essabank.com

Is ESSA Bancorp in the S&P 500?

No, ESSA Bancorp is not included in the S&P 500 index

Is ESSA Bancorp in the NASDAQ 100?

No, ESSA Bancorp is not included in the NASDAQ 100 index

Is ESSA Bancorp in the Dow Jones?

No, ESSA Bancorp is not included in the Dow Jones index

When was ESSA Bancorp the previous earnings report?

No data

When does ESSA Bancorp earnings report?

The next expected earnings date for ESSA Bancorp is 24 January 2025